• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke survivors face high risk of visual problems
Up to six in 10 stroke survivors experience new visual problems prompted by their stroke Related items fromOnMedica Loneliness itself appears not to raise risk of heart attack/stroke NICE wants GPs to prevent 8,000 strokes a year Regular GP pulse checks of elderly patients could prevent strokes, study finds Experts warn of heart risks for people with diabetes Wait and hip measurement better indicator of heart attack risk than obesity
Source: OnMedica Latest News - March 11, 2019 Category: UK Health Source Type: news

NICE publishes new draft guidelines on statins use
"Millions more people should be put on cholesterol-lowering statin drugs," BBC News reports. Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that the drugs should be given to people with an estimated 1 in 10 or more risk of cardiovascular disease (CVD), which includes conditions such as heart disease and stroke. Statins are medicines that can help lower rates of low-density lipoprotein (LDL) cholesterol (so-called "bad" cholesterol) in the blood. High rates of LDL cholesterol can lead to hardening of the arteries, a risk factor for CVDs. At present,...
Source: NHS News Feed - February 12, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research

NICE recommends Xarelto® as a treatment option for reducing secondary events in ACS
The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to follow in Q1 2015.
Source: Pharmacy Europe - January 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness Industry News Cardiovascular medicine Legislation & regulation Patient care acs antiplatelet therapy ATLAS ACS 2 TIMI 51 Latest News TIA Xaltero Source Type: news

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involving the e...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Should I take statins?
Since 80% of cardiovascular disease is caused by lack of exercise, poor diet and smoking, it would be better to address these factors rather than pop a statinShould everyone over 50 be taking statins? asked an editorial in the Lancet last year. No, said an analysis article in last week's BMJ. Statins, in case you've escaped the hype, are drugs that block an enzyme in the liver that's needed to make cholesterol (we make it as well as eat it). Statins reduce levels of low density lipoproteins – the bad cholesterol that furs up arteries and can cause heart disease. But is there any benefit in taking a statin if yo...
Source: Guardian Unlimited Science - October 27, 2013 Category: Science Authors: Luisa Dillner Tags: The Guardian Medical research Health & wellbeing Human biology Drugs Features Life and style Science Source Type: news

Mediterranean diet 'as effective as statins' in reducing heart attack risk
Leading doctors call on medical bodies such as Nice to do more to promote healthy lifestyles rather than relying on cardiovascular drugsPeople at risk of a stroke or heart attack should reduce that risk by adopting the Mediterranean diet rather than necessarily taking statins, leading doctors are urging.Eating more healthily, being more physically active and stopping smoking can be just as effective as starting to take the cholesterol-lowering drugs, they have said in a paper published on Monday. Continue reading...
Source: Guardian Unlimited Science - September 6, 2015 Category: Science Authors: Denis Campbell Health policy editor Tags: Statins Society Heart attack The National Institute for Health and Care Excellence (Nice) NHS & wellbeing Drugs Science Medical research Diets and dieting Source Type: news

Is Your Prescription a Hall Pass or Lottery Ticket?
As much as I love learning, I did not always love school. We moved a lot, and I was too shy to do well as the new kid. At a new high school during my freshmen year, I discovered the joys of the hall pass. Being handed one gave me a feeling of freedom. With it, I was safe to evade the pressures of the classroom and wander the halls aimlessly. If a teacher stopped me to see if I should be in class, all I had to do was show my hall pass, and I'd be on my way. I think of a hall pass as something that is assured to protect you. Let's say a hall pass works at least 8 out of 10 times. There are hall passes, and then, there are l...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

Can Data Simulation Help Evaluate Hta Outcomes Over Time and Facilitate Early Decision-Making? a Case Study of Ticagrelor in Acute Coronary Syndrome in the Uk
In October 2011, the National Institute for Health and Care Excellence (NICE) recommended the use of ticagrelor in adult patients presenting with acute coronary syndrome (ACS) in England and Wales. The relative effectiveness and cost-effectiveness of ticagrelor compared to clopidogrel—the current standard of care in the NHS—were based on results from one large multicentre study including over 18,000 ACS patients. Patients were recruited from October 2006 through to July 2008 and primary trial data analysis, published in September 2009, demonstrated that ticagrelor significantly reduced the rate of death, myocardial inf...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: P Dequen, NJ Cooper, K Abrams Source Type: research

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Feasibility Survey on Outpatient Management of Hypertension In Algeria
Hypertension (HT) is a prevalent condition, contributing risk factor to heart failure, heart attack and stroke. Ambulatory blood pressure monitoring (ABPM) is important for improving the diagnosis and management of HT as recommended by the guidelines published by the NICE in the UK in 2011. However there is a lack of data on the follow up of theses guidelines in the Maghreb countries. We aimed in this survey to assess the management of HT and usage of ABPM in daily practices in Algeria.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: N. Hammoudi-Bendib, L. Mahi, A. Cherif, X. Girerd Source Type: research

NICE recommends heart attack patients take ticagrelor for longer period
Patients who have had a heart attack or stroke should continue to receive the anticoagulant ticagrelor for up to three years after their initial 12-month dose, NICE draft guidance recommends.
Source: GP Online News - August 11, 2016 Category: Primary Care Tags: 15.1 Cardiovascular Problems Source Type: news

10 Changes to Your Morning Routine That Will Transform Your Entire Day
This article originally appeared on BusinessInsider.com
Source: TIME.com: Top Science and Health Stories - September 11, 2017 Category: Consumer Health News Authors: Caroline Praderio / Business Insider Tags: Uncategorized life hacks onetime Source Type: news

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique®), to submit evidence on the clinical and cost effectiveness of ticagrelor 60  mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared with ASA only for secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI) and who are at increased risk of atherothrombotic events. Kleijnen Systematic R eviews Ltd (KSR), in collaboration with Maastricht University Medical Centre+, was commissioned as the evidence review ...
Source: PharmacoEconomics - January 18, 2018 Category: Health Management Source Type: research